Membranoproliferative glomerulonephritis cost-effectiveness of therapy

Jump to navigation Jump to search

Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis cost-effectiveness of therapy

CDC on Membranoproliferative glomerulonephritis cost-effectiveness of therapy

Membranoproliferative glomerulonephritis cost-effectiveness of therapy in the news

Blogs on Membranoproliferative glomerulonephritis cost-effectiveness of therapy

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis cost-effectiveness of therapy

Albeit, there is several strategies for treatment of MPGN, each method has its own indications, however, new medications such as monoclonal antibodies (Rituximab) is demonstrating new path for future treatment of MPGN[1]

References

  1. Michael Rudnicki (2017). "Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies". Hindawi, BioMed Research International.

Template:WH Template:WS